162 results on '"Drelichman, Guillermo"'
Search Results
2. Argentine bone project- 11 years of experience: A study by the Argentine Gaucher Disease Diagnosis and Treatment Group
3. Eliglustat maintains long-term clinical stability in patients with Gaucher disease type 1 stabilized on enzyme therapy
4. Testicular dysfunction at diagnosis in children and teenagers with haematopoietic malignancies improves after initial chemotherapy
5. Case report: De novo SAMD9L truncation causes neonatal-onset autoinflammatory syndrome which was successfully treated with hematopoietic stem cell transplantation
6. ELIKIDS: Baseline characteristics from the eliglustat substrate reduction therapy trial in children with Gaucher disease type 1 or type 3
7. Consequences of late diagnosis and treatment in patients with Gaucher disease type 1: Experience of the Argentine group
8. Eltrombopag for children with chronic immune thrombocytopenia (PETIT2): a randomised, multicentre, placebo-controlled trial
9. Eliglustat compared with imiglucerase in patients with Gaucher's disease type 1 stabilised on enzyme replacement therapy: a phase 3, randomised, open-label, non-inferiority trial
10. P3.03: Allogeneic Hematopoietic Stem Cells Transplantation (AHSCT). Is Still the Sibling Donor the Best Option? One Single Center Experience
11. Foco neurológico en paciente pediátrico con leucemia linfoblástica aguda
12. Testicular dysfunction at diagnosis in children and teenagers with haematopoietic malignancies improves after initial chemotherapy.
13. Iron chelation with deferasirox in adult and pediatric patients with thalassemia major: efficacy and safety during 5 years' follow-up
14. Síndrome 'stroke-like' en leucemia linfoblástica aguda pediátrica
15. Experience with Blinatumomab in Pediatric Patients in Argentina. Multi-Center Study
16. Clinical Consequences of Interrupting Enzyme Replacement Therapy in Children with Type 1 Gaucher Disease
17. A phase 3 study of deferasirox (ICL670), a once-daily oral iron chelator, in patients with β-thalassemia
18. Feohifomicosis por Exserohilum rostratum en un paciente pediátrico con leucemia linfoblástica aguda postransplante de médula ósea
19. Safety, efficacy, and authorization of eliglustat as a first-line therapy in Gaucher disease type 1
20. The road to biosimilars in rare diseases ‐ ongoing lessons from Gaucher disease
21. Addendum to Letter to the Editor: Safety, efficacy, and authorization of eliglustat as a first-line therapy in Gaucher disease type 1
22. Parkinsonisms and Glucocerebrosidase Deficiency: A Comprehensive Review for Molecular and Cellular Mechanism of Glucocerebrosidase Deficiency
23. The road to biosimilars in rare diseases ‐ ongoing lessons from Gaucher disease.
24. Assessment of liver and cardiac iron overload using MRI in patients with chronic anemias in Latin American countries: results from ASIMILA study
25. Combined therapy for type 3 Gaucher disease
26. Bone lesions in type 1 Gaucher disease after improving dose and compliance with imiglucerase
27. Use of trabecular bone score (TBS) as a complementary approach to bone mineral density (BMD) in Gaucher disease patients treated with imiglucerase
28. Maintenance of quality of life in adults with type 1 Gaucher disease previously stabilized on enzyme therapy who were switched to oral eliglustat: 4 year results of the ENCORE trial
29. DOENÇA DE GAUCHER TIPO 1 NO ESQUELETO: REVISÃO DA AMÉRICA LATINA
30. Skeletal involvement in Gaucher disease: An observational multicenter study of prognostic factors in the Argentine Gaucher disease patients
31. Pre motor symptoms of Parkinson disease in Argentinean patients with type 1 Gaucher disease. Preliminary report (P6.380)
32. Four-year follow-up from the ENCORE trial: A randomized, controlled, non-inferiority study comparing eliglustat to imiglucerase in patients with Gaucher disease type 1 stabilized on enzyme replacement therapy
33. Prodromal Clinical Markers of Parkinson disease in Gaucher Disease Individuals
34. Assessment of liver and cardiac iron overload using MRI in patients with chronic anemias in Latin American countries: results from ASIMILA study*.
35. ENCORE, a randomized, controlled, open-label non-inferiority study comparing eliglustat to imiglucerase in Gaucher disease type 1 patients stabilized on enzyme replacement therapy: 24-month results
36. Efficacy and Safety of Deferasirox (Exjade (R)) in Patients with beta-Thalassemia Major Treated for up to 5 Years
37. Efficacy and Safety of Deferasirox (Exjade (R)) in Patients with beta-Thalassemia Major Treated for up to 5 Years
38. Feohifomicosis por Exserohilum rostratumen un paciente pediátrico con leucemia linfoblástica aguda postransplante de médula ósea
39. PETIT and PETIT 2: Treatment with Eltrombopag in 171 Children with Chronic Immune Thrombocytopenia (ITP)
40. Encore - a Randomized, Controlled, Open-Label Non-Inferiority Study Comparing Eliglustat to Imiglucerase in Gaucher Disease Type 1 Patients Stabilized on Enzyme Replacement Therapy: 24-Month Results
41. New Prognostic Factors in the Assessment of Bone Complications in Gaucher Disease. Report from the Argentinian Group for Diagnostic and Treatment for Gaucher Disease
42. Long-term effect of imiglucerase in Latin American children with Gaucher disease type 1: lessons from the International Collaborative Gaucher Group Gaucher Registry
43. ENCORE: A randomized, controlled, open-label non-inferiority study comparing eliglustat to imiglucerase in Gaucher disease type 1 patients on enzyme replacement therapy who have reached therapeutic goals
44. Long-term imiglucerase/alglucerase treatment in Latin American children with type 1 Gaucher disease: Lessons from the International Collaborative Gaucher Group (ICGG) Gaucher Registry
45. Comparison of IV Busulfan and Fludarabine Vs Oral Busulfan Plus Cyclophosphamide As Myeloablative Conditioning Regimens for Acute Leukemias and Myelodisplastic Syndromes
46. Minimal Residual Disease by Flow Cytometry in Children with Acute Lymphoblastic Leukemia. Single-Center Experience
47. Lipid Peroxidation Products In Bone Marrow Plasma (BMp) and Peripheral Blood Plasma (PBp) From Patients with Low Risk Myelodysplastic Syndrome (MDS)
48. Efficacy and Safety of Deferasirox (Exjade®) in Patients with β-Thalassemia Major Treated for up to 5 Years.
49. Autologous Hemopoietic Stem-Cell Transplantation in Patients with Preexisting Cardiac Abnormalities.
50. Inherited Bone Marrow Failure Syndromes in Children: 32 Years Experience in a Single Institution.
Catalog
Books, media, physical & digital resources
Discovery Service for Jio Institute Digital Library
For full access to our library's resources, please sign in.